DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
AG-120 is an investigational drug.
There have been 16 clinical trials for AG-120. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Myeloid. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Celgene Corporation.
There are three US patents protecting this investigational drug and sixty-one international patents.
Recent Clinical Trials for AG-120
|Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)||National Cancer Institute (NCI)||Phase 2|
|Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia||Agios Pharmaceuticals||Phase 1|
|Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for AG-120
Top clinical trial sponsors for AG-120
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AG-120||Start Trial||Therapeutically active compositions and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|AG-120||Start Trial||Therapeutically active compositions and their methods of use||AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)||Start Trial|
|AG-120||Start Trial||Pharmaceutical compositions of therapeutically active compounds||AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|